{"id":206871,"name":"ZYNERBA PHARMACEUTICALS, INC.","slug":"zynerba-pharmaceuticals-inc","state":"PA","country":"United States of America","description":"health/governmental assistance before FDA","totalSpending":400000,"filings":15,"yearlySpending":[{"year":2020,"income":45000},{"year":2021,"income":165000},{"year":2022,"income":80000},{"year":2023,"income":110000}],"issues":[{"code":"GOV","display":"Government Issues"},{"code":"HCR","display":"Health Issues"},{"code":"PHA","display":"Pharmacy"}],"firms":["WATKINS & EAGER PLLC"],"lobbyists":["GREGG HARPER"],"govEntities":["Food & Drug Administration (FDA)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Assist in the development & approval process before the FDA of Zynerba's lead therapeutic for the potential treatment of behavioral symptoms associated with Fragile X Syndrome.","Assist in the development & approval process before the FDA of Zynerba's lead therapeutic for the potential treatment of behavioral symptoms associated with Fragile X Syndrome.","Brief key House & Senate Members and/or appropriate staff on need and justification for this product. Secure letter of support for applications from key House & Senate Members.","Assist in the development & approval process before the FDA of Zynerba's lead therapeutic for the potential treatment of behavioral symptoms associated with Fragile X Syndrome.","Support Zynerba and its partners, and any other of its contractors in its process before the FDA; Troubleshoot inevitable issues and eligibility hurdles to ensure the project is considered for approva"]}